Analysis of serum phosphate control and phosphate binder utilization in incident hemodialysis patients

International Journal of Nephrology and Renovascular Disease

Volumn 7, Issue , 2014, Pages 261-269

  Farrand, Kimberly F ^a   Copley, J Brian ^a   Heise, Jamie ^a   Fridman, Moshe ^b   Keith, Michael S ^a   Poole, Lynne ^c  

^a SHIRE   (United States)

^b AMF Consulting   (United States)

^c Shire Pharmaceuticals   (United Kingdom)

Author keywords

Chronic kidney disease; End stage renal disease; Hyperphosphatemia

Indexed keywords

PARATHYROID HORMONE; PHOSPHATE; PHOSPHATE BINDING AGENT;

AGED; ARTICLE; BLOOD ANALYSIS; COMORBIDITY; CONTROLLED STUDY; DRUG UTILIZATION; FEMALE; HEMODIALYSIS PATIENT; HUMAN; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; OUTPATIENT DEPARTMENT; PATIENT ASSESSMENT; PHOSPHATE BLOOD LEVEL; PHOSPHATE METABOLISM; RETROSPECTIVE STUDY; TREND STUDY;

EID: 84904042922     PISSN: None     EISSN: 11787058     Source Type: Journal    
DOI: 10.2147/IJNRD.S58037     Document Type: Article

References (32)

1. Block GA, Klassen PS, Lazarus JM, Ofsthun N, Lowrie EG, Chertow GM. Mineral metabolism, mortality, and morbidity in maintenance hemodialysis. J Am Soc Nephrol. 2004;15(8):2208-2218.
2. Kestenbaum B, Sampson JN, Rudser KD, et al. Serum phosphate levels and mortality risk among people with chronic kidney disease. J Am Soc Nephrol. 2005;16(2):520-528.
3. Cannata-Andia JB, Roman-Garcia P, Hruska K. The connections between vascular calcification and bone health. Nephrol Dial Transplant. 2011;26(11):3429-3436.
4. National Kidney Foundation. K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease. Am J Kidney Dis. 2003;42(4 Suppl 3):S1-S201.
5. Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Work Group. KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD). Kidney Int Suppl. 2009;(113):S1-S130.
6. Noori N, Sims JJ, Kopple JD, et al. Organic and inorganic dietary phosphorus and its management in chronic kidney disease. Iran J Kidney Dis. 2010;4(2):89-100.
7. Coladonato JA. Control of hyperphosphatemia among patients with ESRD. J Am Soc Nephrol. 2005;16(Suppl 2):S107-S114.
8. Ikizler TA. Dietary protein restriction in CKD: the debate continues. Am J Kidney Dis. 2009;53(2):189-191.
9. Rufino M, de Bonis E, Martín M, et al. Is it possible to control hyperphosphataemia with diet, without inducing protein malnutrition? Nephrol Dial Transplant. 1998;13(Suppl 3):65-67.
10. Shinaberger CS, Greenland S, Kopple JD, et al. Is controlling phosphorus by decreasing dietary protein intake beneficial or harmful in persons with chronic kidney disease? Am J Clin Nutr. 2008;88(6):1511-1518.
11. Kalantar-Zadeh K, Supasyndh O, Lehn RS, McAllister CJ, Kopple JD. Normalized protein nitrogen appearance is correlated with hospitalization and mortality in hemodialysis patients with Kt/V greater than 1.20. J Ren Nutr. 2003;13(1):15-25.
12. Lacson E, Ikizler TA, Lazarus JM, Teng M, Hakim RM. Potential impact of nutritional intervention on end-stage renal disease hospitalization, death, and treatment costs. J Ren Nutr. 2007;17(6):363-371.
13. Pupim LB, Caglar K, Hakim RM, Shyr Y, Ikizler TA. Uremic malnutrition is a predictor of death independent of inflammatory status. Kidney Int. 2004;66(5):2054-2060.
14. Rambod M, Bross R, Zitterkoph J, et al. Association of Malnutrition-Inflammation Score with quality of life and mortality in hemodialysis patients: a 5-year prospective cohort study. Am J Kidney Dis. 2009; 53(2):298-309.
15. Collins AJ, Foley RN, Chavers B, et al. 'United States Renal Data System 2011 Annual Data Report: Atlas of chronic kidney disease and end-stage renal disease in the United States. Am J Kidney Dis. 2012; 59(1 Suppl 1): e1-e420.
16. Becker GJ, Walker RG, Hewitson TD, Pedagogos E. Phosphate levels - time for a rethink? Nephrol Dial Transplant. 2009;24(8):2321-2324.
17. Danese MD, Belozeroff V, Smirnakis K, Rothman KJ. Consistent control of mineral and bone disorder in incident hemodialysis patients. Clin J Am Soc Nephrol. 2008;3(5):1423-1429.
18. Ring T, Sanden AK, Hansen HH, Halkier P, Nielsen C, Fog L. Ultradian variation in serum phosphate concentration in patients on haemodialysis. Nephrol Dial Transplant. 1995;10(1):59-63.
19. Isakova T, Gutiérrez OM, Chang Y, et al. Phosphorus binders and survival on hemodialysis. J Am Soc Nephrol. 2009;20(2):388-396.
20. Gutiérrez OM, Mannstadt M, Isakova T, et al. Fibroblast growth factor 23 and mortality among patients undergoing hemodialysis. N Engl J Med. 2008;359(6):584-592.
21. Melamed ML, Eustace JA, Plantinga L, et al. Changes in serum calcium, phosphate, and PTH and the risk of death in incident dialysis patients: a longitudinal study. Kidney Int. 2006;70(2):351-357.
22. Selvarajah V, Pasea L, Ojha S, Wilkinson IB, Tomlinson LA. Pre-dialysis systolic blood pressure-variability is independently associated with all-cause mortality in incident haemodialysis patients. PLoS One. 2014;9(1):e86514.
23. Pelletier S, Roth H, Bouchet JL, Drueke T, London G, Fouque D; French Phosphorus and Calcium Observatory investigators. Mineral and bone disease pattern in elderly haemodialysis patients. Nephrol Dial Transplant. 2010;25(9):3062-3070.
24. Yavuz A, Ersoy FF, Passadakis PS, et al. Phosphorus control in peritoneal dialysis patients. Kidney Int Suppl. 2008;(108):S152-S158.
25. Young EW, Albert JM, Satayathum S, et al. Predictors and consequences of altered mineral metabolism: the Dialysis Outcomes and Practice Patterns Study. Kidney Int. 2005;67(3):1179-1187.
26. Karamanidou C, Clatworthy J, Weinman J, Horne R. A systematic review of the prevalence and determinants of nonadherence to phosphate binding medication in patients with end-stage renal disease. BMC Nephrol. 2008;9:2.
27. Arenas MD, Malek T, Gil MT, Moledous A, Alvarez-Ude F, Reig-Ferrer A. Challenge of phosphorus control in hemodialysis patients: a problem of adherence? J Nephrol. 2010;23(5):525-534.
28. Lecker SH. Given the science on malnutrition, how does the clinician respond? Practical lessons for and application to the dialysis patient. Clin J Am Soc Nephrol. 2009;4(Suppl 1):S64-S70.
29. Pires A, Adragão T, Pais MJ, Vinhas J, Ferreira HG. Inferring disease mechanisms from epidemiological data in chronic kidney disease: calcium and phosphorus metabolism. Nephron Clin Pract. 2009;112(3): c137-c147.
30. Slatopolsky E, Brown A, Dusso A. Role of phosphorus in the pathogenesis of secondary hyperparathyroidism. Am J Kidney Dis. 2001; 37(1 Suppl 2):S54-S57.
31. Uhlig K, Berns JS, Kestenbaum B, et al. KDOQI US commentary on the 2009 KDIGO Clinical Practice Guideline for the Diagnosis, Evaluation, and Treatment of CKD-Mineral and Bone Disorder (CKD-MBD). Am J Kidney Dis. 2010;55(5):773-799.
32. Lopes AA, Tong L, Thumma J, et al. Phosphate binder use and mortality among hemodialysis patients in the Dialysis Outcomes and Practice Patterns Study (DOPPS): evaluation of possible confounding by nutritional status. Am J Kidney Dis. 2012;60(1):90-101.